Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2′-Deoxy-(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro

References

• Coucke PA, Decosterd LA, Li Y-X, et al. The ribonucleoside diphosphate reductase inhibitor (E)-2′-deoxy-(fluoromethylene)-cytidine as a cytotoxic radiosensitizer in vitro. Cancer Research 1999; 59: 5219–26
   PubMed Web of Science ®Google Scholar
• Knol JA, Walker SC, Robertson JM, et al. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7 day hepatic arterial infusion. Cancer Res 1995; 55: 3687–91
   PubMed Web of Science ®Google Scholar
• Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res 1992; 131: 81–9
   PubMed Web of Science ®Google Scholar
• Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine. Radiat Res 1992; 131: 90–7
   PubMed Web of Science ®Google Scholar
• Li Y-X, Coucke PA, Paschoud N, et al. Potentiation of cytotoxicity and radiosensitization of (E)-2′-deoxy-2′-(fluoromethylene)cytidine by pentoxifylline in vitro. Int J Cancer 1999; 80: 155–60
   PubMed Web of Science ®Google Scholar
• Shewach DS, Ellero J, Mancini WR. Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 1992; 43: 1579–85
   PubMed Web of Science ®Google Scholar
• Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994; 54: 3218–23
   PubMed Web of Science ®Google Scholar
• Shewach DS, Lawrence TL. Radiosensitization of human tumor cells by gemcitabine in vitro. sem. Oncol 1995; 22: 68–71
   Google Scholar
• Fox RM. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. Pharmac Ther 1985; 30: 31–42
   PubMed Web of Science ®Google Scholar
• Riddler SA, Andreson RE, Mellors JW. Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T). Antiviral Res 1995; 27: 189–203
   PubMed Web of Science ®Google Scholar
• Weber G. Biochemical strategy of cancer cells and the design of chemotherapy. G. H. A. Clowes Memorial Lecture. Cancer Res 1983; 43: 3466–92
   PubMed Web of Science ®Google Scholar
• Weber G, Ichikawa S, Nagai M, et al. Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Communic 1990; 2: 129–33
   PubMed Web of Science ®Google Scholar
• Davis MA, Tang H-Y, Maybaum J, et al. Dependence of fluoro-deoxyuridine-mediated radiosensitization on S-phase progression. Int J Radiat Biol 1995; 67: 509–17
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Davis MA, Maybaum J, et al. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells. Int J Radiat Oncol Biol Phys 1992; 22: 499–503
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34: 867–72
   PubMed Web of Science ®Google Scholar
• Levin VA, Prados MR, Wara WM, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995; 32: 75–83
   PubMed Web of Science ®Google Scholar
• Matthews DP, Persichetti RA, Sabol JS, et al. Improved synthesis of (E)-2′-deoxy-2′-(fluoromethylene)cytidine-a potent inhibitor of ribonucleotide diphosphate reductase. Nucleosides Nucleotides Nucleic Acids 1993; 12: 115–23
   Google Scholar
• Snyder RD. Effect of 2′-deoxy-2′-(fluoromethylene) cytidine on the ultraviolet and x-ray sensitivity of HeLa cells. Oncol Res 1994; 6: 177–82
   PubMed Web of Science ®Google Scholar
• Sun L-Q, Li Y-X, Guillou L, et al. Antitumor and radiosensitizing effects of (E)-2′-Deoxy-(fluoromethylene)cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice. Cancer Res 1997; 57: 4023–28
   PubMed Web of Science ®Google Scholar
• Sun L-Q, Li Y-X, Guillou L, et al. (E)-2′-Deoxy-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Cancer Res 1998; 58: 5411–7
   PubMed Web of Science ®Google Scholar
• Toffoli G, Errante D, Corona G, et al. Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms. Cemother 1999; 45: 418–28
   PubMed Web of Science ®Google Scholar
• Uhl V, Phillips TL, Ross GY, et al. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines. Int J Radiat Oncol Biol Phys 1992; 22: 489–94
   PubMed Web of Science ®Google Scholar
• Coucke PA, Cottin E, Azria D, et al. Positive interactive radiosensitization observed in vitro with the combination of two nucleoside analogs (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMdC) and iododeoxyuridine (IdUrd). Eur J Can 2004; 40: 1572–80
   PubMed Web of Science ®Google Scholar
• Kanazawa J, Takahashi T, Akinaga S, et al. The relationship between the antitumor activity and ribonucleotide reductase inhibitory activity of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101,731. Anti-Cancer Drugs 1998; 9: 653–7
   PubMed Web of Science ®Google Scholar
• Hannigan BM, Xu Y-Z, Chubb S, et al. Thymidine kinases: The enzymes and their clinical usefulness. Canc Biother 1993; 8: 189–97
   PubMedGoogle Scholar
• Decosterd LA, Cottin E, Chen X, et al. Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high performance liquid chromotagraphy. Annal Biochem 1999; 270: 59–68
   PubMed Web of Science ®Google Scholar
• Iliakis G, Kurtzmann S. Keynote address: Application of non-hypoxic sensitizers in radiobiology and radiotherapy: Rationale and future prospects. Int J Radiat Oncol Biol Phys 1989; 16: 1235–41
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Matthews DP, Stemerick DM, et al. Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J Am Chem Soc 1991; 113: 7439–40
   Web of Science ®Google Scholar
• McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. JNCI 1996; 88: 1193–203
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA, Bush TL, et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 1994; 54: 1485–90
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Bush TL, Lewis MT, et al. Response of human prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res 1995; 15: 1179–82
   PubMed Web of Science ®Google Scholar
• Piepmeier JM, Rabidou N, Schold SC, et al. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 1996; 56: 359–61
   PubMed Web of Science ®Google Scholar
• Wright PS, Cross-Doersen D, YH'NG JPH, et al. A ribonucleotide reductase inhibitor MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exper Cell Res 1996; 222: 54–60
   PubMed Web of Science ®Google Scholar
• Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994; 30: 391–8
   PubMed Web of Science ®Google Scholar
• Al-Nabulsi I, Takamiya Y, Voloshin Y, et al. Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res 1994; 54: 5614–7
   PubMed Web of Science ®Google Scholar
• Ahluwalia GS, Gao W-Y, Mitsuya H, et al. 2′,3′-didehydro-3′deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5’-triphosphate biosynthesis. Mol Pharmacol 1996; 50: 160–5
   PubMed Web of Science ®Google Scholar
• Pressaco J, Mitrovski B, Erlichman C, et al. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995; 55: 1505–8
   PubMed Web of Science ®Google Scholar
• Gong Y-F, Bechtold CM, Robinson BS, et al. Potentiation of the stavudine anti-human immunodeficiency virus activity by 5-fluorouracil. Antimicrob Agents Chemother 1996; 40: 1329
   PubMed Web of Science ®Google Scholar
• Falcone A, Danesi R, Dargenio F, et al. Intravenous azidothymidine with fluorouracil and leucovorin: A phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996; 14: 729–36
   PubMed Web of Science ®Google Scholar
• Klein HO, Demir G. Multi-enzyme-targeted immunotherapy. A salvage therapy protocol. Anticancer Res 1999; 19: 3451–8
   PubMed Web of Science ®Google Scholar
• Posner MR, Darnowski JW, Weitberg AB, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 1992; 15: 2929–34
   Google Scholar
• Kuo M-L, Kunugi KA, Lindstrom M-J, et al. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 1995; 55: 2800–5
   PubMed Web of Science ®Google Scholar
• Heinemann V, Xu Y-Z, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567–72
   PubMed Web of Science ®Google Scholar
• Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Sem Oncol 1995; 22: 11–8
   PubMed Web of Science ®Google Scholar
• Vokes EE, Stupp R, Haraf D, et al. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil and concomittant radiotherapy for poor prognosis head and neck cancer. Semin Oncol 1995; 22: 47–52
   PubMed Web of Science ®Google Scholar
• Deutsch M, Rewers AB, Redgate ES, et al. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of rat glioma. Int J Radiat Biol 1990; 19: 85–7
   Google Scholar
• Erikson RL, Szybalski W. Molecular radiobiology of human cell lines. III. radiation-sensitizing properties of 5-iododeoxyuridine. Cancer Res 1963; 23: 122–30
   Web of Science ®Google Scholar
• Fornace AJ, Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990; 18: 873–8
   PubMed Web of Science ®Google Scholar
• Phillips TL, Bodell WJ, Uhl V, et al. Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys 1989; 16: 1251–5
   PubMed Web of Science ®Google Scholar
• Copaceanu M-L, Coucke PA, Cottin E, et al. Azidothymidine (AZT) as a potential modifier of radiation response in vitro. Acta Oncol 1995; 34: 213–8
   PubMed Web of Science ®Google Scholar